Ken Griffin In Med Pharmaceuticals Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in In Med Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,725 shares of INM stock, worth $3,308. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,725
Previous 34,009
62.58%
Holding current value
$3,308
Previous $14,000
71.43%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding INM
# of Institutions
19Shares Held
686KCall Options Held
0Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ362KShares$94,0494.44% of portfolio
-
Armistice Capital, LLC New York, NY267KShares$69,4110.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny28.3KShares$7,3580.0% of portfolio
-
Two Sigma Securities, LLC New York, NY15.4KShares$4,0090.0% of portfolio
-
Qube Research & Technologies LTD London, X0200Shares$520.0% of portfolio
About InMed Pharmaceuticals Inc.
- Ticker INM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 908,761
- Market Cap $236K
- Description
- InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in precl...